ArticleFrontiers in oncology2026
Case Report: pulmonary MALT lymphoma with
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (pulmonary MALT lymphoma) is an indolent B-cell lymphoma that can mimic infection, inflammatory disease, or epithelial malignancy. Indeterminate fluorodeoxyglucose-avid abnormalities may complicate staging and lead to overinterpretation of disease extent. Case presentation: A 49-year-old man with no smoking history underwent video-assisted thoracoscopic right lower-lobe superior segmentectomy for a 12 × 9 mm pulmonary nodule. Histopathology and immunohistochemistry supported pulmonary MALT lymphoma, and fluorescence Conclusion: Mild FDG uptake in longstanding pulmonary opacities and an unbiopsied gastrointestinal abnormality should not be interpreted as lymphoma dissemination. Histopathology, immunophenotyping, molecular testing, longitudinal imaging, and pathologic confirmation of suspected additional sites should be integrated before disease extent and treatment response are assigned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.